



SDI Review Form 1.6

Journal Name:	Journal of Advances in Medical and Pharmaceutical Sciences
Manuscript Number:	Ms_JAMPS_28271
Title of the Manuscript:	Alzheimer's: A Disease Fraught with Syndromes, Hypotheses and Theories with attendant intractable Pharmacological Management
Type of the Article	Review paper

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	-I am not sure about the statement that "ACh is known to promote non-amyloidogenic processing and reduce tau phosphorylation by reducing the activity of protein kinase which phosphorylates tau." Could you please provide appropriate reference for this statement? -ChEIs are not able to "inhibit AD progression", they can only slow down the disease progression -regarding current therapy of AD, this reference must be included: Zemek, F. et al. Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf. 2014 Jun;13(6):759-74.	The reference is : Lahiri DK, Farlow MR, Sambamurti K, Greig NH, Giacobini E, Schneider LS. A critical analysis of new molecular targets and strategies for drug development in Alzheimer's disease. Current Drug Targets 4 ,2003:97-112 -Yes, they can only slow down the disease progression. -I will include the reference but it will change the previous reference number and increase it by one.
<u>Minor</u> REVISION comments	-“reduced cerebri amyloid and acetylcholinesterase activity” – cerebral -“the substrate binging cleft of the enzyme” – binding?	This is actually an embarrassing typographical error. It should be cerebral and not cerebri and binding and not binging as you rightly pointed out. Thank you.
<u>Optional/General</u> comments		